TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9422900
Drug: Supine side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine side horizontal position with 3 ml of 0.5% bupivacaine
Study: 8124913
Drug: 3 intravenous
Normalized name: Ammonia N 13 Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravenous pulses of 1000 mg methylprednisolone (MP) on alternate days during the first week
Study: 8124913
Drug: 3 oral
Normalized name: Cytra-3 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 oral pulses of 100 mg prednisolone
Study: 3693807
Drug: Timolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (beta-adrenergic blocker)
Study: 18363758
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied twice daily for 2 weeks, then to both sides for 6 weeks
Study: 18363758
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied to L-sides after initial treatment on P-sides
Study: 18363758
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied to P-sides
Study: 18363758
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied to L-sides
Study: 16597037
Drug: Routine methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine methods (psychotherapy, daub narcotic to glans of penis, and medication for chronic prostatitis)
Study: 14678093
Drug: L-arginine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (12 g orally daily for up to 5 days)
Study: 3594133
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue biological adhesive system (BAS) applied in Group I (42 patients)
Study: 31578136
Drug: Zinc bisglycinate
Normalized name: Citrated zinc bisglycinate
DrugBank: Zinc glycinate (DB14493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc bisglycinate (15 mg elemental zinc)
Study: 27485028
Drug: Hydrocortisone 3
Normalized name: hydrocortisone 3.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 3 mg
Study: 27485028
Drug: Hydrocortisone 6
Normalized name: hydrocortisone 6.67 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 6 mg
Study: 27485028
Drug: Hydrocortisone 12
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 12 mg
Study: 27485028
Drug: Hydrocortisone 24
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 24 mg
Study: 27485028
Drug: Hydrocortisone with
Normalized name: Hydrocortisone with Aloe
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone with RU486 (GR antagonist)
Study: 24999075
Drug: Levonorgestrel intrauterine
Normalized name: Levonorgestrel Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel intrauterine device (LNG-IUD) + metformin
Study: 8215491
Drug: Oral cyclosporine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine, 2.5 mg/kg per day
Study: 8215491
Drug: Oral cyclosporine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine, 1.25 mg/kg per day
Study: 8215491
Drug: Oral cyclosporine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine, 3.75 mg/kg per day
Study: 3317328
Drug: Cefonicid administered
Normalized name: cefonicid
DrugBank: Cefonicid (DB01328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefonicid administered once daily, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Study: 3317328
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered every eight hours, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Study: 31804741
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1000 mg intravenous, administered two weeks apart
Study: 21406695
Drug: Superoxidized aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superoxidized aqueous solution
Study: 18982248
Drug: Tablet administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered 45 min before food (pre-feed)
Study: 18982248
Drug: Tablet administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered on an empty stomach (fasted)
Study: 18982248
Drug: Tablet administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered after food (fed)
Study: 18982248
Drug: Tablet administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered pre-feed (in six volunteers)
Study: 9589652
Drug: rhGH (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.1 mg/kg.day)
Study: 19436670
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 8 mg once daily, increased to 16 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Study: 19436670
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate (AML) 5 mg once daily, increased to 10 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Study: 15196586
Drug: Metformin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin IR tablet (500 mg)
Study: 11417922
Drug: Bitemporal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitemporal treatment (after right unilateral treatment failure)
Study: 444956
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg thrice daily for seven days)
Study: 25240012
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine intracervical injection 5 min prior to LNG-IUS insertion
Study: 25240012
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, 400 mg) 1 h prior to LNG-IUS insertion
Study: 23099972
Drug: Topical/intracameral anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical/intracameral anesthesia (group 1)
Study: 17903693
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg every day
Study: 17903693
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg every day
Study: 15649162
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (100 mg.kg(‐1) after induction, 100 mg.kg(‐1) in pump prime, 100 mg.kg(‐1) after weaning from bypass)
Study: 15649162
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aprotinin and tranexamic acid (same dosages as above)
Study: 12237596
Drug: 1-day intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Study: 12237596
Drug: 3-day intramuscular
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Study: 1324238
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg/day
Study: 6831819
Drug: gallopamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil (50 mg)
Study: 6831819
Drug: propafenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: propafenone (150 mg)
Study: 3793333
Drug: nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (10 mg)
Study: 3793333
Drug: verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (80 mg)
Study: 6831819
Drug: quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinidine (250 mg)
Study: 27740721
Drug: MF-MDI 50
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-MDI 50 mcg BID
Study: 27740721
Drug: MF-MDI 100
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-MDI 100 mcg BID
Study: 27740721
Drug: MF-MDI 200
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-MDI 200 mcg BID
Study: 25857939
Drug: Stretching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching treatment with a prefabricated orthosis and stretching exercises
Study: 25857939
Drug: Strengthening treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthening treatment with a prefabricated orthosis, stretching, and strengthening exercises
Study: 20419494
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 320 mg PO
Study: 20419494
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg IV + Metoclopramide 20 mg IM (no megestrol acetate)
Study: 1606999
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg and 100 mg)
Study: 4075074
Drug: Semantic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic treatment (4 sessions over one week)
Study: 4075074
Drug: Semantic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic treatment (8 sessions over two weeks)
Study: 4075074
Drug: Phonological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological treatment (4 sessions over one week)
Study: 4075074
Drug: Phonological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological treatment (8 sessions over two weeks)
Study: 27286139
Drug: Agomelatine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (15 mg/day for patients ≥30 kg and 25 mg/day for patients ≥45 kg)
Study: 27286139
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) (20 mg/day for participants <30 kg and 30 mg/day for patients ≥30 kg)
Study: 20685951
Drug: Whole-grain foods
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain foods (3 daily portions)
Study: 12564610
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg sibenadet via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Study: 12564610
Drug: Placebo via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Study: 10627444
Drug: Intensive ALL-type
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines (240 mg/m²) and cyclophosphamide (3 g/m²) with prophylactic cranial irradiation (12 Gy)
Study: 10627444
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy for patients with less than 70% tumor regression on day 33
Study: 1735396
Drug: Diclofenac 37.5
Normalized name: diclofenac 37.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 37.5 mg or 75 mg
Study: 1735396
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg or 50 mg
Study: 1735396
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg or 10 mg
Study: 3544689
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg tid
Study: 3544689
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg bid
Study: 3544689
Drug: Both 2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 2-dose and 3-dose regimens
Study: 24456823
Drug: Temsirolimus 25mg
Normalized name: TEMSIROLIMUS 25MG/ML INJ,SOLN
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 25mg weekly
Study: 24456823
Drug: Temsirolimus with
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus with megestrol acetate 80 mg bid for three weeks alternating with tamoxifen 20mg bid for three weeks
Study: 23250594
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy (MENS) in addition to standard treatment (n=36)
Study: 23250594
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy (MENS) in combination with cortexin (n=38)
Study: 23250594
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy using massage and gymnastics (n=31)
Study: 9180672
Drug: DHEAS (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS (7.5 mg)
Study: 1610024
Drug: Pemirolast 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemirolast 50 mg BID
Study: 1610024
Drug: Pemirolast 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemirolast 25 mg BID
Study: 24642702
Drug: Cognitive-based-behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-based-behavioral therapy (CBT)
Study: 22345500
Drug: Alteplase delivered
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase delivered through a microcatheter embedded within the thrombus at 1 mg per minute, not exceeding 100 mg total
Study: 17986242
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (20 mug type 6, 40 mug type 11, 40 mug type 16, and 20 mug type 18)
Study: 11849196
Drug: Dofetilide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide 1.0 mg twice daily for 23 days and once on day 24 (continuous dosing)
Study: 11849196
Drug: Dofetilide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide 1.0 mg single dose on days 1, 5, 10, 17, and 24 (intermittent dosing)
Study: 11849196
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo capsules under the same regimen as group 1)
Study: 7234399
Drug: Cytological examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytological examination of cerebrospinal fluid with histiomonocytic counts greater than 10 M. elements/l and granulocytic peaks greater than 2 M. elements/l
Study: 23408577
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) therapy for 5 years followed by a 5-year treatment-free period (placebo arm of the FLEX trial)
Study: 21555291
Drug: Pharmacists providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists providing information regarding medication's name (93.3%)
Study: 21555291
Drug: Pharmacists providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists providing dosage schedule (92.8%)
Study: 21555291
Drug: Pharmacists advising
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists advising daily medication intake (92.6%)
Study: 12472369
Drug: Thrombolytic drugs
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic drugs
Study: 11078635
Drug: iobitridol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: iobitridol (20 ml)
Study: 11078635
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution (20 ml)
Study: 9093234
Drug: Suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive therapy for disseminated or invasive fungal infections; details on dosage and duration not available.
Study: 8287659
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg orally)
Study: 18398080
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment (LDL-C target of 70 mg/dL or lower, SBP target of 115 mm Hg or lower)
Study: 18398080
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (LDL-C target of 100 mg/dL or lower, SBP target of 130 mm Hg or lower)
Study: 9664269
Drug: Sequential pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pneumatic compression (SPC) with a pressure of 40‐60 mmHg for 2 hours/day for 2 weeks
Study: 2905064
Drug: Suspension therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension therapy (abrupt discontinuation of neuroleptics)
Study: 30796110
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (10,000 lux)
Study: 30796110
Drug: Placebo light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo light therapy
Study: 12599240
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha (4.5 microg/kg per week until hemoglobin concentration >or= 12 g/dL, then 1.5 microg/kg per week)
Study: 2491362
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily
Study: 27193497
Drug: Ubiquinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (200 mg/day)
Study: 23037460
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg intravenously before CECT imaging
Study: 12206794
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of dystrophin cDNA
Study: 7907098
Drug: Antipsychotic withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic withdrawal (n = 64)
Study: 7907098
Drug: Continued use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued use of antipsychotics (n = 207)
Study: 28235817
Drug: Involvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement of posterior limb of internal capsule
Study: 28235817
Drug: ICH encompassing
Normalized name: SODIUM CHLORIDE 5 mg in 1 mL / MALACHITE GREEN 5 mg in 1 mL TOPICAL SOLUTION [Nox-Ich]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICH encompassing thalamus and posterior limb of internal capsule
Study: 24436950
Drug: Periodontal nonsurgical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal nonsurgical treatment including oral hygiene instruction and scaling and root planing
Study: 24436950
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction only
Study: 17062645
Drug: Solution-Finding Approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Finding Approach (SFA)
Study: 10580352
Drug: sulodexide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulodexide (600 lipoprotein lipase releasing units [LRU] by im route per day for 30 consecutive days, followed by 500 LRU by oral route per day for a further 30 days)
Study: 10580352
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment (cleansing with physiological solution and elastic compression with short‐extensibility, removable bandages)
Study: 9772600
Drug: Xinjikang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinjikang capsule (XJK)
Study: 1927852
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone (400 mg/day for 4 weeks, then 200 mg/day)
Study: 1927852
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone (with >75% reduction in ectopy)
Study: 31455688
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g fat
Study: 31455688
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g fat
Study: 7491880
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g fat
Study: 31455688
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g fat
Study: 26084869
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic management with continuous insulin infusion (target glucose 4.4‐6.1 mmol/l)
Study: 26084869
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic management with intermittent bolus insulin (target glucose <11.1 mmol/l)
Study: 24631949
Drug: NEPA (NETU
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA (NETU 300 mg + PALO 0.50 mg) with oral dexamethasone (DEX)
Study: 19604523
Drug: L-carnitine 2
Normalized name: L-Carnitine 250mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 2 g/d and simvastatin 20 mg
Study: 19604523
Drug: simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin monotherapy 20 mg
Study: 16824762
Drug: Gait training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gait training with functional neuromuscular stimulation (FNS) using intramuscular (IM) electrodes
Study: 15047004
Drug: Serum alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alkaline phosphatase and intact parathyroid hormone levels
Study: 8024910
Drug: Beta 1
Normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta 1 blocker (metoprolol)